The Honest Guide to Cagrilintide: What Patients and Doctors Actually Say

Cagrilintide at a glance:

• Drug class: Long-acting amylin analog
• Manufacturer: Novo Nordisk
• Route: subcutaneous injection
• Typical frequency: once weekly
• Half-life: approximately 7 days
• Receptor target: amylin receptors (calcitonin receptor + RAMP)

Let's cut through the marketing on Cagrilintide and look at what the data actually say. Cagrilintide is an engineered amylin analog with extended half-life suitable for weekly dosing, and the result for users is: monotherapy phase 2 showed weight loss of 6-10%; combination with semaglutide pushed total weight loss above 17%.

What is Cagrilintide?

Cagrilintide is an engineered amylin analog with extended half-life suitable for weekly dosing. Amylin co-released with insulin from beta cells suppresses glucagon, slows gastric emptying, and increases satiety.

Cagrilintide is manufactured by Novo Nordisk. Cagrilintide is not currently approved by the FDA for general human use. Available evidence comes from early-phase clinical work. We do not endorse self-administration of unapproved compounds.

The drug class long-acting amylin analog works by acting at the amylin receptors (calcitonin receptor + RAMP). We cover the details below.

How Cagrilintide Works in the Body

Cagrilintide is an engineered amylin analog with extended half-life suitable for weekly dosing. Amylin co-released with insulin from beta cells suppresses glucagon, slows gastric emptying, and increases satiety. The receptor target — amylin receptors (calcitonin receptor + RAMP) — drives the downstream effects users care about: monotherapy phase 2 showed weight loss of 6-10%; combination with semaglutide pushed total weight loss above 17%.

The pharmacokinetics matter for daily use. Cagrilintide has a half-life of approximately 7 days, which determines how often it is dosed. The standard route of administration is subcutaneous injection, and the typical schedule is once weekly.

For more detail on the underlying biology, see our breakdown of how Cagrilintide works.

Who Uses Cagrilintide?

Cagrilintide is most relevant for people whose situation maps to its approved indications: none yet — investigational.

People who should avoid Cagrilintide include those with the following:

• allergy to the active ingredient or any excipient
• pregnancy or breastfeeding (per label)
• conditions specifically called out in the prescribing information

Common and Serious Side Effects

The most commonly reported side effects of Cagrilintide include:

• nausea
• decreased appetite
• diarrhea

Serious risks — uncommon but worth knowing — include:

• limited long-term data

We have a more detailed breakdown in our Cagrilintide side-effects guide.

Cagrilintide vs Alternatives

The closest approved comparator is pramlintide (immediate-release amylin analog used with insulin). If you are weighing Cagrilintide against another option, our comparison pages include Cagrilintide Side Effects: 7 Things to Watch For (and How to Manage Them), Cagrilintide Results: Realistic Expectations vs. Trial Headlines, Why Cagrilintide Costs So Much (and 5 Ways to Pay Less).

Bottom Line

If you're considering Cagrilintide, the most useful next step is usually a conversation with a clinician who knows the full landscape of options — not just the one they prescribe most often. Evidence remains preliminary; we recommend caution and clinician oversight. If you are considering Cagrilintide, talk to a licensed clinician first — particularly if you take other medications.

Frequently Asked Questions

Related Reading

• Cagrilintide Side Effects: 7 Things to Watch For (and How to Manage Them)
• Cagrilintide Results: Realistic Expectations vs. Trial Headlines
• Why Cagrilintide Costs So Much (and 5 Ways to Pay Less)
• Cagrilintide and Weight Loss: What Trials Show vs. Real Life
• Is Retatrutide Right for You? An Evidence-Based Breakdown
• What Nobody Tells You About Retatrutide Side Effects

Sources

• Le Roux CW et al. Survodutide for the Treatment of Obesity — Phase 2. Lancet 2024;403:888.
• Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). NEJM 2022;387:205.
• Jastreboff AM et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — Phase 2 Trial. NEJM 2023;389:514.

This page is informational only and is not medical advice. Consult a licensed clinician before starting, stopping, or changing any medication.